BCM
MCRB icon

Bayesian Capital Management’s Seres Therapeutics MCRB Stock Holding History

Bayesian Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,550
Closed -$29.3K – 865
2024
Q3 		$29.3K Buy
+1,550
New +$31.4K ﹤0.01% 634

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's MCRB Position: Q4 2024 in Review

Bayesian Capital Management sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 1,550 shares — an estimated $29.3K sold.

Bayesian Capital Management first reported a position in MCRB in Q3 2024 and held it in 1 quarter. The position peaked at $29.3K in Q3 2024. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

  • Bayesian Capital Management reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 1,550 Seres Therapeutics shares in Q4 2024, an estimated $29.3K.
  • Bayesian Capital Management first reported a position in Seres Therapeutics in Q3 2024 and held it in 1 quarter.
  • Bayesian Capital Management's Seres Therapeutics position peaked at $29.3K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.